Updated May 27, 2026Expert Reviewed

Best Semaglutide 2.4mg Providers Ranked & Reviewed

The 2.4mg max dose is one of the most-searched semaglutide tiers. We compare every telehealth provider that offers compounded or brand-name semaglutide at this dose, ranked by independent score, monthly price, and patient reviews.

WeightLossRankings.org is reader-supported. When you buy through links on our site, we may earn an affiliate commission. Learn more

Always verify pricing and state availability on the provider's website before signing up.How our reviews work →

Methodology & sources

Providers in this variant are scored against our published six-factor rubric[1], then filtered to match the specific dose shown in the page title.

Published Phase 3 efficacy for semaglutide 2.4 mg (~14.9% mean weight loss over 68 weeks) comes from the STEP 1 trial[2]. The SURMOUNT-5 head-to-head published in 2025 directly compared tirzepatide and semaglutide[3].

Quick Picks: Top 1

#ProviderScore
1Coby Health7.3Visit

Detailed Reviews

1

Coby Health

Best for: Budget-conscious patients comfortable with no-membership cash-pay compounded GLP-1 who don't require pharmacy-partner transparency

7.3

Chicago/Springfield IL DTC telehealth marketplace (Coby Health LLC, BBB file opened 3/2025) offering compounded semaglutide from $99/mo (6-mo bundle, 0.25mg) and compounded tirzepatide from $179/mo (6-mo bundle, 2.5mg). LegitScript Certified (seal 38387067). Clinical care via Beluga Health P.A. (Dr. Jonah Mink network). No membership fee. CAUTION: does NOT publicly disclose compounding pharmacy partners.

Score Breakdown

Value25%
8
Effectiveness25%
7
User Experience15%
7.5
Trust & Safety15%
6
Accessibility10%
7.5
Support10%
8
2.4mg from $249/mo
Visit Coby Health

Frequently Asked Questions

Sources & methodology — as of May 2026
  1. 1.Weight Loss Rankings — GLP-1 Pricing Index 2026 (our independent dataset)WeightLossRankings.org.
  2. 2.STEP 1 Trial — Once-Weekly Semaglutide in Adults with Overweight or Obesity (Wilding JPH et al.)New England Journal of Medicine.PMID: 33567185.
  3. 3.SURMOUNT-5 Trial — Tirzepatide vs. Semaglutide Head-to-Head in Obesity (Garvey WT et al.)New England Journal of Medicine.PMID: 40334173.